OrthoPediatricsvsMerck & Company

KIDS and MRK stock compared: price, dividend, valuation and results, from SEC filings.

KIDS

OrthoPediatrics Corp.

$31.74

Value $802M

-2.37%
KIDS's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

OrthoPediatrics (KIDS) has a market value of $802M and Merck & Company (MRK) $331B. Over the last year, with dividends, KIDS moved +91.0% and MRK +44.8%. Dividend yield: KIDS none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    KIDS$802M

    MRK$331B

    MRK is 412 times KIDS

  • Revenue, 12 months

    KIDS$264M

    MRK$67.4B

    MRK is 255 times KIDS

  • Net income, 12 months

    KIDS-$34M

    MRK$2.5B

  • Operating margin

    KIDS-9.4%

    MRK–

  • ROIC

    KIDS-4.4%

    MRK3.9%

    8.3 points apart

  • P/E

    KIDS–

    MRK134.8

  • Dividend yield

    KIDS0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    KIDS-48.2%

    MRK+93.0%

    141.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

KIDS-48.2%

MRK+93.0%

10020020222023202420252026
Returns by period
PeriodKIDSWith dividendsMRKWith dividends
1 year since November 19, 2025+91.0%Price +91.0%+44.8%Price +40.7%
3 years since November 20, 2023-0.3%-0.1% a yearPrice -0.3%+42.7%+12.6% a yearPrice +30.2%
5 years since November 19, 2021-48.2%-12.3% a yearPrice -48.2%+93.0%+14.1% a yearPrice +65.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

KIDSOrthoPediatricsMRKMerck & Company

Valuation

KIDSMRK
Valuation
Price$31.74$133.72
Market value$802M$331B
Enterprise value (EV)$859M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B2.47.4
EV/EBIT–78.7
Free cash flow yield0.4%4.5%

Results and growth

KIDSMRK
Results and growth
Revenue, 12 months$264M$67.4B
Net income, 12 months-$34M$2.5B
Free cash flow, 12 months$3.2M$14.7B
Earnings per share, 12 months-$1.43$0.98
Revenue growth, year on year15.5%1.3%
Revenue growth a year, past+27.2%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

KIDSMRK
Margins and returns on capital
Gross margin73.8%71.8%
Operating margin-9.4%–
Net margin-12.8%3.6%
ROIC-4.4%3.9%
ROE-9.9%5.2%

Balance sheet

KIDSMRK
Balance sheet
Cash$44M$9.7B
Total debt$101M$53.8B
Net debt / EBITDA–5.7
Interest cover-9.4×2.4×

Dividends and buybacks

KIDSMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: KIDS or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, OrthoPediatrics or Merck & Company?

By market value, Merck & Company ($331B) is about 412.1 times OrthoPediatrics ($802M), at today's prices.

How did KIDS and MRK stock do over the last 5 years?

Since November 19, 2021, KIDS's price moved -48.2% and MRK's +65.7%. With dividends: KIDS -48.2% (-12.3% a year), MRK +93.0% (+14.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, KIDS or MRK?

The dividend yield at today's price is none for OrthoPediatrics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, OrthoPediatrics or Merck & Company?

Over the last twelve months, the net margin was -12.8% for OrthoPediatrics and 3.6% for Merck & Company, and the operating margin -9.4% and –. Revenue was $264M and $67.4B.

Which is the better investment, OrthoPediatrics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.